Log in
OTCMKTS:SPHRY

STARPHARMA HOLD/S Stock Forecast, Price & News

$10.40
+0.15 (+1.46 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.40
Now: $10.40▼
$10.60
50-Day Range
$10.25
MA: $11.30▼
$12.60
52-Week Range
$3.68
Now: $10.40▼
$13.05
Volume586 shs
Average Volume1,554 shs
Market Capitalization$418.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.48 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:SPHRY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.starpharma.com
Phone61-3-8532-2700
EmployeesN/A

Debt

Debt-to-Equity Ratio0.03
Current Ratio5.48
Quick Ratio5.40

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.40 million
Price / Sales95.21
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.56 per share
Price / Book18.57

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares40,280,000
Market Cap$418.91 million
Next Earnings DateN/A
OptionableNot Optionable
$10.40
+0.15 (+1.46 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPHRY News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHRY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











STARPHARMA HOLD/S (OTCMKTS:SPHRY) Frequently Asked Questions

How has STARPHARMA HOLD/S's stock price been impacted by Coronavirus?

STARPHARMA HOLD/S's stock was trading at $6.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SPHRY shares have increased by 67.2% and is now trading at $10.40.
View which stocks have been most impacted by COVID-19.

Are investors shorting STARPHARMA HOLD/S?

STARPHARMA HOLD/S saw a increase in short interest in September. As of September 30th, there was short interest totaling 4,300 shares, an increase of 168.8% from the September 15th total of 1,600 shares. Based on an average daily trading volume, of 3,700 shares, the days-to-cover ratio is presently 1.2 days.
View STARPHARMA HOLD/S's Short Interest.

Who are some of STARPHARMA HOLD/S's key competitors?

Some companies that are related to STARPHARMA HOLD/S include National Research (NRC), Precigen (PGEN), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), Auxly Cannabis Group (CBWTF), Bioanalytical Systems (BASI), NanoViricides (NNVC), NanoViricides (NNVC), Cleveland BioLabs (CBLI), ProMIS Neurosciences (ARFXF), Inhibitor Therapeutics (INTI) and AIkido Pharma (AIKI).
View all competitors.

Who are STARPHARMA HOLD/S's key executives?

STARPHARMA HOLD/S's management team includes the following people:
  • Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 56)
  • Mr. Nigel J. Baade, CFO & Company Sec.
  • Dr. A. Eglezos BSc(Hons), Ph.D., MBA, VP of Bus. Devel.
  • Dr. Jeremy R. Paull BSc (Hons), Ph.D., VP of Devel. & Regulatory Affairs
  • Dr. David J. Owen BSc(Hons) Ph.D., VP of Research

What is STARPHARMA HOLD/S's stock symbol?

STARPHARMA HOLD/S trades on the OTCMKTS under the ticker symbol "SPHRY."

How do I buy shares of STARPHARMA HOLD/S?

Shares of SPHRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is STARPHARMA HOLD/S's stock price today?

One share of SPHRY stock can currently be purchased for approximately $10.40.

How big of a company is STARPHARMA HOLD/S?

STARPHARMA HOLD/S has a market capitalization of $418.91 million and generates $4.40 million in revenue each year.

What is STARPHARMA HOLD/S's official website?

The official website for STARPHARMA HOLD/S is www.starpharma.com.

How can I contact STARPHARMA HOLD/S?

STARPHARMA HOLD/S's mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The company can be reached via phone at 61-3-8532-2700 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.